Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8461 to 8475 of 8944 results

  1. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  2. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  3. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  4. Breathlessness

    Discontinued Reference number: GID-NG10387

    NICE guideline
    Discontinued

  5. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

    In development Reference number: GID-TA11690 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

    Diagnostics guidance
    Discontinued

  10. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  11. Hernia

    Discontinued Reference number: GID-CGWAVE0771

    NICE guideline
    Discontinued

  12. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued

  13. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  14. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

    Safe staffing guideline
    Discontinued

  15. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    In development Reference number: GID-TA11278 Expected publication date: TBC

    Technology appraisal guidance
    In development